Aditya Bardia, MD, MPH

Dr Bardia provides his opinion on the current state of the ER+/HER2- treatment landscape and where elacestrant belongs in the current treatment paradigm.

Taking a closer look at the EMERALD trial, Dr Bardia shares key efficacy outcomes from the sub-group analyses 1) of patients with no prior chemotherapy and 2) comparing elacestrant to fulvestrant or AI.

Dr Bardia discusses the mechanism of action of elacestrant, how elacestrant compares to other SERDS, and introduces the EMERALD trial.

Dr Bardia talks about the role of biomarker testing and provides an overview of factors which may contribute to a clinician’s choice of treatment strategy for patients with ER+/HER- mBC.

Aditya Bardia, MD, MPH briefly explains metastatic ER+/HER2- breast cancer, and reviews existing treatment options for patients with ER+/HER2- mBC.

Aditya Bardia, MD, MPH, discusses the efficacy of sacituzumab govitecan in patients with triple-negative breast cancer.

Aditya Bardia, MBBS, MPH, discusses the value of liquid biopsies in the treatment landscape of breast cancer. The real value of liquid biopsy in this space lies in providing oncologists with insight on what’s happening in tumor evolution.

Aditya Bardia, MBBS, MPH, discusses the development of targeted therapies for patients with triple-negative breast cancer. He says these approaches can be divided into 3 different categories.

Aditya Bardia, MD, MPH, attending physician, Massachusetts General Hospital, Harvard Medical School, discusses the dual targeting of the HER2 receptor in patients with breast cancer.

Aditya Bardia, MD, MPH, discusses recent advancements in the field of breast cancer.

Aditya Bardia, MD, MPH, Attending Physician, Massachusetts General Hospital, Harvard Medical School, gives an overview of the Snapshot assay for breast cancer.